Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Oncology

Standard of Care Treatment & Mayo Clinic Protocol

At a Glance

Treatment for perihilar cholangiocarcinoma (pCCA) depends on the tumor's stage. Options include radical surgery followed by chemotherapy, liver transplantation through the strict Mayo Clinic Protocol for localized tumors, or a combination of chemotherapy and immunotherapy for advanced disease.

The path forward for pCCA is determined by where the tumor is and whether it can be safely removed. Your treatment plan should be decided by a multidisciplinary tumor board [1]. It is important to know that while curative-intent treatments exist, pCCA remains an aggressive disease with a poor overall prognosis, and surgeries carry significant risks.

1. Resectable: The Surgical Path

If the tumor is “resectable,” surgeons believe they can safely remove it with clear (R0) margins [2].

  • Radical Surgery: This is not a minor procedure. It involves major hepatectomy (removing part of the liver), removing the bile ducts and nearby lymph nodes, and performing complex vascular and biliary reconstruction to reconnect everything [3][4]. The actual 5-year overall survival rate following an R0 resection is roughly 30% [5].
  • The BILCAP Protocol: After surgery, the global standard for preventing recurrence is taking an oral chemotherapy drug called capecitabine for six months [6]. This is known as the BILCAP protocol and is standard of care in Western countries [7].

2. Localized Unresectable: The Transplant Path

Sometimes a tumor hasn’t spread to other organs but wraps around major blood vessels, making radical surgery too dangerous. In highly selected cases, a liver transplant may be an option via the Mayo Clinic Protocol [8].

  • Strict Eligibility: This pathway is heavily restricted. Patients generally only qualify if the tumor is small (typically <3 cm) and there is absolute proof that the cancer has not spread to the lymph nodes [9][10].
  • The Process: It begins with neoadjuvant chemoradiation (chemotherapy and radiation) to shrink and stabilize the tumor [11]. If the tumor stays stable, the patient receives a transplant. For those who qualify and complete the protocol, 5-year survival is approximately 52%, though early vascular complications are a risk [8][12].

3. Advanced or Metastatic: The Systemic Path

If the cancer has spread beyond the liver or involves major blood vessels extensively, treatment shifts to systemic therapy—medications that travel through the whole body [13].

  • Chemotherapy + Immunotherapy: The modern standard of care includes traditional chemotherapy (gemcitabine and cisplatin) combined with immune checkpoint inhibitors (like durvalumab or pembrolizumab) [14][13]. This combination helps the immune system recognize and attack cancer cells alongside the chemotherapy [14].

Common questions in this guide

What does it mean if my pCCA tumor is 'resectable'?
A tumor is considered resectable if surgeons believe they can safely remove it with clear margins. This involves a major operation to remove part of the liver, bile ducts, and nearby lymph nodes, followed by complex reconstruction.
What is the BILCAP protocol?
The BILCAP protocol is the standard of care after surgery to help prevent the cancer from returning. It involves taking an oral chemotherapy drug called capecitabine for six months following your operation.
Who qualifies for the Mayo Clinic Protocol for a liver transplant?
The Mayo Clinic Protocol is a highly restricted transplant option for localized, unresectable tumors. Patients generally only qualify if their tumor is smaller than 3 centimeters and there is absolute proof the cancer has not spread to the lymph nodes.
What treatments are available for advanced or metastatic pCCA?
If the cancer has spread beyond the liver, treatment typically shifts to systemic therapy. The modern standard of care combines traditional chemotherapy drugs with immune checkpoint inhibitors to help your immune system fight the cancer.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my imaging, is my tumor considered 'resectable' by standard surgery or 'unresectable' but localized?
  2. 2.If I have surgery, what exactly will be removed (radical surgery)?
  3. 3.Will I start the BILCAP protocol (capecitabine) after surgery?
  4. 4.Am I a candidate for the Mayo Clinic Protocol for liver transplantation, and does this hospital perform it?
  5. 5.If my cancer is advanced, will my treatment include immunotherapy along with chemotherapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Multi-Disciplinary Care of Hilar Cholangiocarcinoma: Review of Guidelines and Recent Advancements.

    Padmanaban V, Ruff SM, Pawlik TM

    Cancers 2023; (16(1)) doi:10.3390/cancers16010030.

    PMID: 38201457
  2. 2

    Radial margin status should be determined in resected perihilar cholangiocarcinoma.

    de Wilde RF, Groot Koerkamp B

    Hepatobiliary surgery and nutrition 2019; (8(5)):557-559 doi:10.21037/hbsn.2019.07.19.

    PMID: 31673558
  3. 3

    Effects of portal vein resection and hepatic artery resection on long-term survival in Klatskin tumor: a meta-analysis.

    Song Y, Zhang Y, Zhen Z, Huang Z

    World journal of surgical oncology 2022; (20(1)):230 doi:10.1186/s12957-022-02692-1.

    PMID: 35821140
  4. 4

    Impact of Combined Vascular Resection and Reconstruction in Patients with Advanced Perihilar Cholangiocarcinoma.

    Kuriyama N, Komatsubara H, Nakagawa Y, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021; (25(12)):3108-3118 doi:10.1007/s11605-021-05004-2.

    PMID: 33884578
  5. 5

    Actual Long-Term Survival Outcome of 403 Consecutive Patients with Hilar Cholangiocarcinoma.

    Kang MJ, Jang JY, Chang J, et al.

    World journal of surgery 2016; (40(10)):2451-9 doi:10.1007/s00268-016-3551-9.

    PMID: 27206402
  6. 6

    Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.

    Bridgewater J, Fletcher P, Palmer DH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(18)):2048-2057 doi:10.1200/JCO.21.02568.

    PMID: 35316080
  7. 7

    Chemotherapy for Biliary Tract Cancer in 2021.

    Sasaki T, Takeda T, Okamoto T, et al.

    Journal of clinical medicine 2021; (10(14)) doi:10.3390/jcm10143108.

    PMID: 34300274
  8. 8

    Single-center experience of liver transplantation for perihilar cholangiocarcinoma.

    Ahmed O, Vachharajani N, Chang SH, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2022; (24(4)):461-469 doi:10.1016/j.hpb.2021.08.940.

    PMID: 34465528
  9. 9

    Selected Patients with Unresectable Perihilar Cholangiocarcinoma (pCCA) Derive Long-Term Benefit from Liver Transplantation.

    Azad AI, Rosen CB, Taner T, et al.

    Cancers 2020; (12(11)) doi:10.3390/cancers12113157.

    PMID: 33121179
  10. 10

    Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease.

    Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al.

    Annals of surgery 2018; (267(5)):797-805 doi:10.1097/SLA.0000000000002574.

    PMID: 29064885
  11. 11

    Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma.

    Hewitt DB, Brown ZJ, Pawlik TM

    Cancers 2022; (14(9)) doi:10.3390/cancers14092208.

    PMID: 35565335
  12. 12

    Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma: multicentre, retrospective cohort study.

    Hoogwater FJH, Kuipers H, de Meijer VE, et al.

    BJS open 2023; (7(2)) doi:10.1093/bjsopen/zrad025.

    PMID: 37032423
  13. 13

    Hilar cholangiocarcinoma: expert consensus statement.

    Mansour JC, Aloia TA, Crane CH, et al.

    HPB : the official journal of the International Hepato Pancreato Biliary Association 2015; (17(8)):691-9 doi:10.1111/hpb.12450.

    PMID: 26172136
  14. 14

    Long-term survival after multidisciplinary treatment including durvalumab for recurrent perihilar cholangiocarcinoma.

    Miyata T, Nagayama T, Nishiki H, et al.

    Clinical journal of gastroenterology 2026; (19(3)):627-631 doi:10.1007/s12328-026-02301-8.

    PMID: 41779092

This page explains treatment options for perihilar cholangiocarcinoma for educational purposes only. Always consult a multidisciplinary tumor board to determine the safest and most effective treatment plan for your specific case.

Get notified when new evidence is published on Perihilar cholangiocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.